Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
7.29 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
149
Market Cap
6023.14M
P/E
12.83

Momentum Score

…

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.29
Low
8.85
High
52 Week Price Range
8.10
Low
8.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Grifols is a global healthcare company that develops and manufactures plasma-derived therapies and clinical diagnostic systems, supported by a plasma collection network. Long-term growth may be driven by rising demand for immunoglobulins and other plasma proteins, expansion of diagnostics in emerging markets, and product development. The company appears positioned in a specialized, recurring-revenue segment with high barriers to entry that could support durable cash flows.

Material risks include reliance on plasma supply and regulatory approvals, competitive and pricing pressures in biologics, and significant leverage that could limit strategic flexibility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.29
Dividend Yield
-
Revenue TTM
7421.00M
Revenue Per Share
10.85
Gross Profit TTM
2804.32M
Debt / Equity
1.83
ROE
6.93%
Net Debt
8814.33M
ROCE
7.07%
Diluted EPS TTM
0.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 614.85M 444.00M 224.02M 361.26M 350.45M
Minority interest -98.00M -55.89M -114.90M -62.87M -82.52M
Net income 401.74M 156.92M 59.31M 208.28M 182.80M
Selling general administrative 1063.00M 1144.01M 1259.53M 1190.42M 1061.51M
Selling and marketing expenses - - 107.14M - -
Gross profit 2858.44M 2794.54M 2494.57M 2231.53M 1962.60M
Reconciled depreciation 450.00M 437.90M 441.92M 407.86M 359.77M
Ebit - 1046.57M 735.57M 704.16M 595.62M
Ebitda 1250.03M 1484.46M 1182.00M 1112.03M 955.39M
Depreciation and amortization - 437.90M 446.42M 407.86M 359.77M
Operating income 1250.03M 1192.02M 799.40M 805.68M 595.06M
Other operating expenses 6271.35M 6020.37M 5792.58M 5361.77M 4370.61M
Interest expense 628.00M 739.94M 516.06M 362.63M 233.81M
Tax provision 115.00M 231.19M 27.21M 90.11M 85.13M
Interest income 34.00M 44.42M 62.33M 33.86M 11.55M
Net interest income -605.00M -701.12M -574.14M -462.67M -266.44M
Income tax expense 114.57M 231.19M 43.35M 90.11M 85.13M
Total revenue 7521.39M 7212.38M 6591.98M 6063.97M 4933.12M
Total operating expenses 1608.41M 1602.52M 1695.17M 1529.33M 1400.09M
Cost of revenue 4662.94M 4417.84M 4097.41M 3832.44M 2970.52M
Total other income expense net -635.18M -748.02M -575.38M 121.72M 54.39M
Net income from continuing ops 500.00M 212.81M 138.29M 271.15M 265.33M
Net income applicable to common shares - - - 208.28M 182.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19703.98M 21405.24M 21441.05M 21533.98M 19233.83M
Intangible assets 2726.98M 2926.13M 1207.55M 2949.15M 1636.95M
Other current assets 99.86M 87.17M 1653.72M 81.81M 64.08M
Total liab 12102.96M 12798.22M 13468.57M 13076.43M 11086.80M
Total stockholder equity 5269.79M 5883.73M 5827.17M 6129.94M 6096.64M
Deferred long term liab - - - 1622.64M 633.24M
Other current liab 791.36M 508.33M 445.13M 504.82M 407.60M
Common stock 119.56M 119.60M 119.60M 119.60M 119.60M
Capital stock 120.00M 119.60M 119.60M 119.60M 1030.33M
Retained earnings 300.00M 156.92M 42.32M 208.28M 182.80M
Other liab - - - 2051.73M 682.36M
Good will 6830.44M 7403.06M 6802.13M 7011.91M 6228.90M
Other assets - - -13.62M 1930.41M 882.61M
Cash 825.18M 979.78M 529.58M 547.98M 655.49M
Total current liabilities 2017.90M 2156.15M 2325.44M 1955.85M 3474.31M
Current deferred revenue - 70.86M 39.19M 37.83M 43.54M
Net debt 8814.33M 9105.84M 10443.38M 9202.15M 8668.81M
Short term debt 385.86M 639.66M 1013.48M 681.27M 2394.18M
Short long term debt 410.00M 523.13M 790.81M 578.92M 2345.61M
Short long term debt total 9639.51M 10085.62M 10972.95M 9750.12M 9324.31M
Other stockholder equity 5264.18M 776.28M 1216.77M 748.51M 746.54M
Property plant equipment - - - 4168.49M 3343.15M
Total current assets 5070.88M 5727.54M 6451.90M 4653.59M 5510.28M
Long term investments 460.00M 528.97M 565.11M 2548.89M 2359.97M
Net tangible assets - - - -2208.48M -1135.97M
Short term investments 23.00M 21.18M 116.14M 43.26M 2029.11M
Net receivables 851.22M 1079.32M 692.86M 754.82M 495.48M
Long term debt 8074.00M 8421.11M 8215.30M 8154.26M 6104.97M
Inventory 3294.62M 3560.10M 3459.28M 3201.36M 2259.35M
Accounts payable 840.69M 852.30M 813.11M 731.92M 628.99M
Accumulated other comprehensive income -113.95M 4830.92M 4448.47M 5053.55M 5047.70M
Non currrent assets other 1347.54M 167.72M 2222.01M 54.06M 4.14M
Non current assets total 14633.09M 15677.70M 14989.15M 16880.39M 13723.56M
Capital lease obligations 1082.00M 1141.38M 1111.33M 1016.94M 873.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -52.00M 886.67M -397.64M -1978.82M 9.82M
Change to liabilities - - - 80.21M 40.45M
Total cashflows from investing activities -578.78M 886.67M -397.64M -1978.82M -29.39M
Net borrowings -119.00M -111.49M -116.39M -177.37M 1878.52M
Total cash from financing activities -528.80M -1358.71M 186.04M -173.49M 1472.92M
Change to operating activities - - - -9.01M -7.08M
Net income 401.85M 444.00M 59.31M 361.26M 350.45M
Change in cash -38.57M 450.20M -18.40M -2127.63M 2095.96M
Begin period cash flow 863.26M 529.58M 547.98M 2675.61M 579.65M
End period cash flow 824.69M 979.78M 529.58M 547.98M 2675.61M
Total cash from operating activities 1046.61M 902.17M 208.28M -10.87M 596.98M
Depreciation 449.83M 437.90M 441.92M 407.86M 359.77M
Other cashflows from investing activities - 1448.93M -80.45M - -
Dividends paid 127.95M 0.96M 0.00M -0.59M -258.95M
Change to inventory -96.96M 25.82M -427.10M -600.25M -157.47M
Change to account receivables -31.99M -41.88M -53.14M -80.17M -16.81M
Sale purchase of stock -128.95M 0.00M 0.00M -3.46M -125.70M
Other cashflows from financing activities -81.97M -1246.26M 5.47M -65.16M 1940.26M
Change to netincome - - - -17.79M 195.31M
Capital expenditures 264.90M 371.37M 295.42M 375.56M 315.09M
Change in working capital -24.99M 22.38M -362.84M -609.22M -140.91M
Other non cash items 219.92M -2.10M 69.89M -170.77M 27.66M
Free cash flow 781.71M 530.80M -87.14M -386.43M 281.89M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GIFOF
Grifols S.A
-
-%
7.29 12.83 10.22 0.81 0.97 1.93 8.92
LLY
Eli Lilly and Company
-1.20
0.09%
1347.11 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson
5.53
2.07%
272.67 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc
-0.20
0.07%
286.20 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation
-
-%
480.00 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Grifols S.A

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174

34 935 71 22 00

25258

Name Title Year Born
Mr. Steven Francis Mayer J.D. Exec. Chairman 1960
Mr. Raimon Grifols Roura Co-CEO & Exec. Director 1964
Mr. Víctor Grifols Deu Co-CEO & Exec. Director 1977
Mr. Alfredo Arroyo Guerra CFO & VP 1958
Mrs. Eva Bastida Tubau Corp. VP and Director of Scientific & Medical Affairs NA
Ms. Nuria Pascual Lapeña VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer 1964
Mr. David Ian Bell Gen. Counsel & Chief Corp. Devel. Officer 1954
Mr. Mateo Florencio Borrás Humbert Corp. VP & Chief HR Officer 1956
Ms. Maria Teresa-Rioné Llano Chief Communications Officer 1965
Ms. Montserrat Gaja Llamas Chief HR Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…